WINZERLAER STR. 2, JENA, 2M
Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Enters Underwriting Agreement for $150 Million Offering
Unaudited Condensed Consolidated Financial Statements – March 31, 2026
Corporate Presentation AAV + Renal Strategy May 2026
Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Deed of Amendment to the Articles of Association
Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis